Entera Bio Ltd.
ENTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Entera Bio Ltd. (ENTX) is listed under Biotechnology. With a market capitalization of $510.8M, it sits in small-cap territory. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Market Cap
$510.8M
Beta
1.40
P/E (TTM)
—
P/E (Fwd)
-5.36
EPS (TTM)
$-0.35
EPS (Fwd)
$-0.55
ROE
-138.9%
ROA
-46.0%
Cash
$11.3M
Total Debt
$425,000
Free CF
-$6.7M
52W Change
35.2%
Annual Financials
Cash vs Debt
Where ENTX stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, ENTX finished 84.76% above its 150-day moving average ($1.64) and 74.14% above its 200-day moving average ($1.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENTX overbought or oversold?
At the August 31, 2026 close, ENTX's RSI(14) was 49.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $11.3M in cash and $425K in debt, ENTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$6.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -138.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $134K (2022) to $42K (2025), a 69% decline worth watching.
With cash comfortably exceeding debt, ENTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ENTX.